Drug Type Fusion protein |
Synonyms HST101, LIB-003, LIB003 |
Target |
Mechanism PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | Phase 3 | CN | 21 Jun 2024 | |
Atherosclerosis | Phase 3 | CN | 21 Jun 2024 | |
Atherosclerotic occlusive disease | Phase 3 | FR | 20 Jun 2022 | |
Atherosclerotic occlusive disease | Phase 3 | DE | 20 Jun 2022 | |
Atherosclerotic occlusive disease | Phase 3 | NO | 20 Jun 2022 | |
Atherosclerotic occlusive disease | Phase 3 | ES | 20 Jun 2022 | |
Atherosclerotic occlusive disease | Phase 3 | GB | 20 Jun 2022 | |
Hypercholesterolemia | Phase 3 | FR | 20 Jun 2022 | |
Hypercholesterolemia | Phase 3 | DE | 20 Jun 2022 | |
Hypercholesterolemia | Phase 3 | ES | 20 Jun 2022 |
Phase 3 | 922 | utucqtreuv(ffkexxmztv) = syjnpnmyva hqineezqfl (hnqdvwrued ) Met View more | Positive | 29 May 2024 | |||
Placebo | fhdcqgswfw(frrrkvtvnm) = dqezthhybs zitkwunbgh (vpbwvcyolq ) | ||||||
Phase 3 | 166 | Lerodalcibep 300 mg monthly | zbrfqiehxe(tpmbidkjjs) = vryndnjvmg toupholzoy (apzggwqdhv ) View more | Positive | 29 May 2024 | ||
Inclisiran 284 mg on Day 1 and 90 | zbrfqiehxe(tpmbidkjjs) = fadzfmqoyk toupholzoy (apzggwqdhv ) View more | ||||||
Phase 3 | 922 | Lerodalcibep 300 mg | zhyqvafkwj(uzywcynhfh) = rfsgauuwsr hsqeznycyt (ayhnxhgbcn ) Met View more | Positive | 08 Apr 2024 | ||
Phase 3 | 421 | pjnlahsqwz(aryjcnvpkq) = jsghcdwrje xatbysfejn (oygnfwjwon ) | Positive | 07 Apr 2024 | |||
Phase 3 | 478 | byefrxqtos(ksegaakrkk) = sszjugydpy dlhhypmwoa (ofuqiuhrts ) View more | Positive | 28 Aug 2023 | |||
placebo | byefrxqtos(ksegaakrkk) = qpsubeujzw dlhhypmwoa (ofuqiuhrts ) View more | ||||||
NCT03847974 (AHA2019) Manual | Phase 2 | 32 | fiaectmdlj(jdksbpatob) = LIB was well tolerated with all AEs considered mild and not drug related. Injection site reactions were minimal and considered mild when present. uagtmpswtf (rrengcstpo ) View more | Positive | 11 Nov 2019 | ||
Placebo |